This year, 2007, marks the 30th anniversary of the first percutaneous coronary intervention, in the form of a percutaneous transluminal coronary angioplasty (PTCA) or balloon angioplasty, by Andreas Gruentzig.<br/> 1 It is also the 20th anniversary of the first report of the use of a stent to maintain vessel patency following balloon angioplasty.<br/> 2 Up until recently, the major limitation to stent implantation was restenosis, or renarrowing, at the site of stent implantation, leading to recurrence of angina. Th s occurred in between 10 to 50% of patients. In 2000, the first reports of a revolutionary new stent, the drug-eluting stent began to emerge, with early promises of zero restenosis.<br/> 3 In 2003, the fi rst drug-eluting stent was commercialised, coated with the immunosuppressive agent sirolimus, leading to the sirolimus-eluting stent, and followed in 2004 by the paclitaxel-eluting stent. The trials performed that led to the commercialisation of drug-eluting stents were in simple lesions, to reduce the number of confounding factors.<br/> 4 The patients studied in these trials make up only 25% of the typical patient population seen in a cardiac catheterisation laboratory. For the remaining 75%, it was extrapolated that these drug-eluting stents would be safe and efficacious, but that assumption required proving.

stent thrombosis, stents
P.W.J.C. Serruys (Patrick)
Erasmus University Rotterdam
Boston Scientific Corporation, Serruys, Prof. Dr. P.W.J.C. (promotor)
Erasmus MC: University Medical Center Rotterdam

Ong, A.T.L. (2007, September 7). The Unrestricted Use of Paclitaxel-Eluting Stents and Sirolimus-Eluting Stents in the Rotterdam T-SEARCH and RESEARCH Registries: Studies on Efficacy, Safety, Stent Thrombosis, Cost Effectiveness and the Future. Erasmus University Rotterdam. Retrieved from